Exelixis Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Good day, everybody. Thanks for joining us at the Bank of America London Healthcare Conference. My name is Jason Gerberry. I'm one of the biotech analysts at BofA, and I am pleased to be introducing our next company at the event Exelixis and joined by Andrew Peters, SVP of Strategy at Exelixis and coming fresh off the ESMO medical meeting and some recent updates for the company. But I'm going to turn it over to Andrew as maybe short prepared remarks just regarding Exelixis and the latest and greatest, and then we'll jump into Q&A.
Yes. Thanks, Jason, and thank you for the invitation. Glad to be in London here with everyone. So before I begin, I want to say I'm going to be making forward-looking statements. So please see our relevant SEC filings for appropriate disclosures and risks about our business.
So for those who aren't familiar with Exelixis, we're a commercial oncology company, with our lead product,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
